Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

The cost-effectiveness of alendronate in the management of osteoporosis.

Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J.

Bone. 2008 Jan;42(1):4-15. Epub 2007 Nov 12.

PMID:
18156107
2.
3.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
4.

Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.

Borgström F, Johnell O, Jönsson B, Zethraeus N, Sen SS.

Bone. 2004 Jun;34(6):1064-71.

PMID:
15193554
5.
6.

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.

Johnell O, Jönsson B, Jönsson L, Black D.

Pharmacoeconomics. 2003;21(5):305-14.

PMID:
12627984
7.

Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.

Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002. Epub 2013 Nov 12.

PMID:
24231131
8.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
9.

Cost-effectiveness of alendronate for the treatment of osteopenic postmenopausal women in Japan.

Moriwaki K, Komaba H, Noto S, Yanagisawa S, Takiguchi T, Inoue H, Toujo T, Fukagawa M, Takahashi HE.

J Bone Miner Res. 2013 Feb;28(2):395-403. doi: 10.1002/jbmr.1755.

10.

Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.

Schousboe JT, Taylor BC, Fink HA, Kane RL, Cummings SR, Orwoll ES, Melton LJ 3rd, Bauer DC, Ensrud KE.

JAMA. 2007 Aug 8;298(6):629-37.

PMID:
17684185
11.

Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.

Schousboe JT, Nyman JA, Kane RL, Ensrud KE.

Ann Intern Med. 2005 May 3;142(9):734-41.

PMID:
15867405
12.

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.

Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM.

Arch Intern Med. 2006 Jun 12;166(11):1209-17.

PMID:
16772249
13.

Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.

Mori T, Crandall CJ, Ganz DA.

Osteoporos Int. 2017 May;28(5):1733-1744. doi: 10.1007/s00198-017-3940-4. Epub 2017 Feb 17.

PMID:
28210776
14.

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.

Jansen JP, Gaugris S, Bergman G, Sen SS.

Curr Med Res Opin. 2008 Mar;24(3):671-84. doi: 10.1185/030079908X260998. Epub 2008 Jan 24.

PMID:
18221588
15.

Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.

Ito K, Elkin EB, Girotra M, Morris MJ.

Ann Intern Med. 2010 May 18;152(10):621-9. doi: 10.7326/0003-4819-152-10-201005180-00002.

16.

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA.

Osteoporos Int. 2007 Aug;18(8):1047-61. Epub 2007 Feb 28.

PMID:
17333449
17.

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland.

Schwenkglenks M, Lippuner K.

Osteoporos Int. 2007 Nov;18(11):1481-91. Epub 2007 May 26.

PMID:
17530156
18.

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.

Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL.

J Am Geriatr Soc. 2005 Oct;53(10):1697-704.

PMID:
16181168
19.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
20.

Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Berto P, Maggi S, Noale M, Lopatriello S.

Aging Clin Exp Res. 2010 Apr;22(2):179-88. doi: 10.3275/6816. Epub 2010 Feb 9.

PMID:
20145427

Supplemental Content

Support Center